The stock market continued what has been a turbulent period with another drop Feb. 12 attributed to concerns over artificial intelligence, experts said. The Nasdaq Composite fell 1.5%, while the broad ...

Stocks edged lower as investors considered surprisingly strong labor-market data, while AI jitters continued to pressure software and financial shares. Major U.S. benchmarks were mixed most of the day ...

The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite catapulted 57%, 70%, and 142%, respectively, during Trump's first term -- and they've delivered an encore performance since his January ...

NEW YORK, Feb 6 (Reuters) - An artificial intelligence-driven shakeout in the heavyweight technology sector is set to keep stock investors on edge in the coming week while a barrage of data could ...

The S&P 500 fell for a third day in a row as the week’s selloff broadened beyond tech. The Dow Jones Industrial Average fell 593 points, or 1.2%. The S&P 500 dropped 1.2%. The Nasdaq Composite slid ...

Don't sweat the decline in Nvidia stock, CNBC's Jim Cramer said Thursday. Calling Nvidia the GOAT — the greatest of all time — Cramer likened the AI chip king's industry prowess and resiliency to that ...

US stocks dropped Thursday, continuing a recent patch of volatility, as Wall Street grappled with persistent nerves about artificial intelligence and economic data showed the labor market weakened ...

Vanguard Total Stock Market ETF VTI accurately represents the large-cap US stock market, allowing its low fee and efficient portfolio to carve out a long-term edge. This exchange-traded fund tracks ...

Last week, the IHSG Composite Index plunged by 8 percent, wiping out an estimated $80 billion in market value. For much of 2025, there was an interesting puzzle in Indonesia’s capital and equity ...

NEW YORK (AP) — The U.S. stock market sank in mixed trading on Tuesday, while gold and silver bounced higher after their latest sell-off. The S&P 500 fell 0.8% and pulled further from its all-time ...

After announcing plans to go public at the top of the year, Eikon Therapeutics has now revealed the proceeds it hopes to pull in from its initial stock offering: $273.5 million. The oncology biotech ...